Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD2O-positive, low-grade non-Hodgkin's lymphoma [3]

British Journal of Haematology

Volumn 112, Issue 4, 2001, Pages 1085-1086

  Bauduer, F ^a  

^a CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

Author keywords

Autoimmune haemolytic anaemia; Cold agglutinins; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

COLD AGGLUTININ; HEMOGLOBIN; RITUXIMAB;

AGED; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; DRUG EFFICACY; DRUG TOLERABILITY; HEMOLYSIS; HUMAN; LETTER; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE;

EID: 0035049290     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02622-3.x     Document Type: Letter

References (2)

1. Rituxan in the treatment of cold agglutinin disease
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program